Therapeutic Human Gene Editing with Dr. David Liu

https://ark-invest.com/podcast/ep106-therapeutic-human-gene-editing/

Over the past five to 10 years, development in the field of human gene editing has advanced at an unprecedented speed. We are now living in an age where therapeutic human gene editing is already a reality for some of us. Today we are joined by Dr. David Liu to discuss these exciting developments. Dr. Liu is a Richard Merkin Professor, Director of the Merkin Institute of Transformative Technologies and Healthcare, Vice-Chair of the Faculty at the Broad Institute of Harvard and MIT, and the Co-founder or Founder of nine biotech or therapeutics companies. He’s published over 195 scientific papers and is the inventor of over 75 issued patents. Today he introduces us to the three main forms of modern genome editing, how they work, their benefits, and their limitations. He explains how the development of CRISPR had an enormous impact on the reach and scope of this field and describes some of the massive developments achieved by his labs in base editing and prime editing. Tune in today to hear how these different types of modalities might be best suited for different types of therapeutic interventions and Dr. Liu’s thoughts on whether or not one method will replace another. Find out if either of these technologies is more amenable to addressing polygenic diseases, the roles and complications of viral and non-viral delivery vectors, and how Dr. Liu believes these technologies will extend in the future. For all this and more, tune in today! 

Dr. David Liu is not affiliated with LPL Financial.